About Sensydia
Sensydia helps medical professionals assess how well a patient's heart is working without putting instruments inside the body. Its Cardiac Performance System is designed to provide critical cardiac measurements in real time. The assessment technology uses artificial intelligence.
Sensydia operates from Valencia, California. Anthony Arnold is president and chief executive officer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | Oct 19, 2026 | $8,904,819of $10.8M target | 10 | $890K | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| May 2, 2023 | May 15, 2023 | $7,799,784of $8.8M target | 23 | $339K | EquityRule 506(b) | Form D ↗ |
| Jul 10, 2020 | Jul 23, 2020amended Aug 18, 2020 | $4,124,330fully sold | 25 | $164K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jul 20, 2017 | Aug 2, 2017 | $3,726,119of $4.0M target | 11 | $338K | EquityRule 506(b) | Form D ↗ |
| Mar 29, 2016 | Apr 5, 2016amended Aug 1, 2016 | $1,953,795fully sold | 13 | $150K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, five offerings | $26,508,847 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Sensydia
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Oct 13, 2026 | Funding | Undisclosed | Sensydia funding announcement ↗ |
Why Investors Backed Sensydia
Sensydia is developing a noninvasive cardiac measurement system for clinical use. It is designed for offices, hospitals and clinics. The system provides critical cardiac readings in real time. Its assessment technology uses artificial intelligence.
Progress so far
Sensydia enrolled the first patient in a CPS study in April 2025. It appointed Rusty Page president in May 2025.
We wrote this summary from public statements by Sensydia and its investors. It is not investment advice.
Sensydia in the News
Leadership Team
Executive officers and directors listed on Sensydia's Form D filed Oct 19, 2026.
Earlier filings also listed Victoria Grace (director, last listed May 2023), Bradford Jones (director, last listed Aug 2020), Thomas Bruggere (president and director, last listed Aug 2017) and G. Jones (director, last listed Aug 2017).